June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Different characteristics predict good visual outcomes in patients with CRVO vs BRVO; hypertension is associated with good outcome in CRVO but not BRVO
Author Affiliations & Notes
  • Peter A Campochiaro
    Ophthalmology and Neuroscience, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland, United States
  • Raafay Sophie
    Ophthalmology and Visual Sciences, University of Louisville , Louisville, Kentucky, United States
  • Ann Clark
    Genentech, Inc., South San Francisco, California, United States
  • Na Lu
    Genentech, Inc., South San Francisco, California, United States
  • Carlos Quezada-Ruiz
    Genentech, Inc., South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Peter Campochiaro, Aerpio Therapeutics (F), Aerpio Therapeutics (C), Alimera (F), Alimera (C), Allegro (F), Allegro (C), Allegro (I), Allergan (F), Allergan (C), Applied Genetic Technologies (C), AsclipiX (F), AsclipiX (C), Genentech, Inc. (F), Genentech, Inc. (C), Genzyme (F), Graybug (C), Graybug (I), Intrexon (C), Merck (C), Oxford Biomedica (F), Regeneron (F), Regenxbio (F), Regenxbio (C), Rxi (F), Rxi (C); Raafay Sophie, None; Ann Clark, Genentech, Inc. (E); Na Lu, Genentech, Inc. (E); Carlos Quezada-Ruiz, Genentech, Inc. (E)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4626. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter A Campochiaro, Raafay Sophie, Ann Clark, Na Lu, Carlos Quezada-Ruiz; Different characteristics predict good visual outcomes in patients with CRVO vs BRVO; hypertension is associated with good outcome in CRVO but not BRVO. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4626.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To identify patient characteristics that predict visual and anatomic outcomes in patients with RVO treated with ranibizumab.

Methods : Patients who completed month (M) 12 of HORIZON (N=386, 205 branch RVO [BRVO] and 181 central RVO [CRVO]) were included. Forty-two variables were analyzed by univariate logistic regression for correlation with 3 outcomes at HORIZON M12: BCVA≥20/40, change from baseline (BL) BCVA≥15 letters, and CFT≤250µm. Variables with overall effect p-values<0.20 were evaluated by multivariable logistic regression using backward selection.

Results : In BRVO patients, good BL BCVA (P<0.0001, odds ratio (OR)=1.09), male gender (P=0.0147, OR=2.48), and normal BL hematocrit (Hct; P=0.0050, high vs normal OR=0.82 and low vs normal OR=0.26) predicted BCVA≥20/40; high BL CFT (P=0.0016, OR=1.003) and normal BL Hct (P=0.0041, high vs normal OR=0.33 and low vs normal OR=0.31) modestly predicted gain in BCVA≥15 letters; and large amount of subretinal fluid modestly predicted CFT≤250µm (P=0.398, OR=1.01). In CRVO patients, good BL BCVA (P<0.0001, OR=1.10), never smoker (P=0.0108, OR=2.80), and young age (P=0.0023, OR=0.95) predicted BCVA≥20/40; hypertension (P=0.0024, OR=4.47), never smoker (P=0.0405, OR=2.13), young age (P<0.0001, OR=0.91), and reduced diastolic ocular perfusion pressure (OPP) at HORIZON M12 (P=0.0027, OR=0.91) predicted gain in BCVA≥15 letters; and young age (P=0.0089, OR=0.96), increased systolic OPP at HORIZON M12 (P=0.0065, OR=1.05), and lower mean Hct (P=0.450, high vs normal OR=0.45 and low vs normal OR=2.81) predicted CFT≤250µm.

Conclusions : There is very little overlap between predictors of good visual outcomes or edema resolution in BRVO and CRVO patients, suggesting important differences between these two disease processes that are often grouped together. For CRVO but not BRVO, young age and never smoking predicted good outcomes. A possible explanation is that factors associated with atherosclerosis (older age and smoking) may be detrimental. Paradoxically, hypertension was associated with good visual outcome in CRVO, possibly because it helps to promote perfusion (supported by beneficial effect of high systolic OPP). Additional studies are needed to evaluate whether acute lowering of blood pressure has a negative impact on visual outcomes in patients with CRVO during anti-VEGF treatment.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×